Kevin Healey
Direttore/Membro del Consiglio presso YM BioSciences Australia Pty Ltd.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Charles Pizzey | M | - |
Vision Systems Pty Ltd.
Vision Systems Pty Ltd. Medical SpecialtiesHealth Technology Vision Systems Pty Ltd. develops, manufactures, and distributes technology products and services to the healthcare markets. It produces automated system solutions and vitro diagnostic instruments for cancer detection. The company was founded in 1984 and is headquartered in Mount Waverley, Australia. | 31 anni |
Philip Whitehead | M | 72 |
Vision Systems Pty Ltd.
Vision Systems Pty Ltd. Medical SpecialtiesHealth Technology Vision Systems Pty Ltd. develops, manufactures, and distributes technology products and services to the healthcare markets. It produces automated system solutions and vitro diagnostic instruments for cancer detection. The company was founded in 1984 and is headquartered in Mount Waverley, Australia. | - |
David M. Duncanson | M | - |
Vision Systems Pty Ltd.
Vision Systems Pty Ltd. Medical SpecialtiesHealth Technology Vision Systems Pty Ltd. develops, manufactures, and distributes technology products and services to the healthcare markets. It produces automated system solutions and vitro diagnostic instruments for cancer detection. The company was founded in 1984 and is headquartered in Mount Waverley, Australia. | - |
George Edward McGuiness | M | - |
Vision Systems Pty Ltd.
Vision Systems Pty Ltd. Medical SpecialtiesHealth Technology Vision Systems Pty Ltd. develops, manufactures, and distributes technology products and services to the healthcare markets. It produces automated system solutions and vitro diagnostic instruments for cancer detection. The company was founded in 1984 and is headquartered in Mount Waverley, Australia. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Andrew John MacDonald | M | 64 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 anni |
Mark Rowsthorn | M | 69 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 13 anni |
Geoffrey Norman Vaughan | M | 91 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 13 anni |
Gavan Flower | M | 51 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | - |
Roderick Lyle | M | 69 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 anni |
Christopher J. Burns | M | - |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 10 anni |
Robert Watson | M | 68 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 anni |
Gregg Smith | M | - |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Australia | 12 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Kevin Healey
- Contatti personali